POM: Prescription only medicine
This information is intended for use by health professionals
AdultsRespiratory tract infections and skin and soft tissue infections - the usual dose is 250mg or 500mg four times daily or 500mg or 1g twice daily depending on the severity and site of infection.Urinary tract infections - the usual dose is 500mg four times daily or 1g twice daily. This may need to be increased for severe or chronic infections. Prolonged intensive therapy is needed for complications such as prostatitis and epididymitis.
ElderlyAs for adults. Patients with impaired renal or hepatic function should be monitored as modifications of the dosage schedule may be required.
Paediatric populationThe usual dose is 25 to 50 mg/kg/day total, given in two or four equally divided doses. For otitis media daily doses from 75 to 100mg/kg in divided doses every 6 to 12 hours are recommended. Maximum dose 4g per day.Cefradine may be taken without regard to meals.All patients irrespective of age and weight: In the case of severe or chronic infection larger doses of up to 1g four times daily may be given. Administration should be continued for a minimum of 48-72 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. For infections caused by haemolytic strains of streptococci, a minimum of 10 days treatment is recommended to guard against the risk of rheumatic fever or glomerulo-nephritis. For the treatment of chronic urinary tract infections, frequent bacteriological and clinical appraisal is necessary during therapy and may be necessary for several months afterwards. Persistent infections may require treatment for several weeks.Smaller doses than those indicated above should not be used. Doses for children should not exceed those recommended for adults. As cefradine is available in both injectable and oral forms, patients may be changed from injection to capsules at the same dosage level.
Dosage in renal impairment:For patients not on dialysis: The following dosage schedule guideline is based on a dosage of 500mg 6 hourly and on creatinine clearance:
|Creatinine Clearance||Dose||Time interval|
|More than 20ml/min||500mg||6 hours|
|Less than 5 ml/min||250mg||12 hours|
|250mg||At start of haemodialysis|
|250mg||6-12 hours after start|
|250mg||36-48 hours after start|
|250mg||At start of next haemodialysis if >30 hours after previous dose.|
FertilityAlthough animal studies have shown no teratogenic effects, safety in pregnancy has not been established.
PregnancyAs with all medicines, use should be avoided in pregnancy especially in the first trimester, unless considered essential by the physician.
Breast-feedingCefradine is excreted in breast milk and therefore should be used with caution in lactating mothers.
Since the medicine may cause dizziness, patients should be cautioned about operating hazardous machinery, including automobiles.
|Infections and infestations|
|Frequency unknown:||Vaginitis, candidal overgrowth, candidiasis|
|Blood and lymphatic system disorders|
|Frequency unknown:||Eosinophilia, blood disorders (including thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia)|
|Immune system disorders|
|Frequency unknown:||Fever, athralgia, serum sickness-like reactions, anaphylaxis|
|Frequency unknown:||Confusion, sleep disturbances|
|Nervous system disorders|
|Frequency unknown:||Hypersensitivity, hyperactivity, hypertonia, dizziness, nervousness|
|Frequency unknown:||Diarrhoea, nausea, glossitis, heartburn|
|Rarely:||Vomiting, abdominal discomfort,|
|Frequency unknown:||Liver, enzyme disturbances, transient hepatitis, cholestatic jaundice|
|Skin and subcutaneous tissue disorders|
|Frequency unknown:||Rashes, toxic epidermal necrolysis, pruritis, urticaria, erythema multiforme, Stevens-Johnson syndrome, oedema|
|Renal and urinary disorders|
|Frequency unknown:||Reversible interstitial nephritis|
|General disorders and administration site conditions|
|Frequency unknown:||Tightness in the chest|
|Frequency unknown:||Elevation of blood urea nitrogen, serum creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphates, positive direct Coombs' test|
|Musculoskeletal and connective tissue disorder|
|Frequency unknown:||joint pain|
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The symptoms of cefradine overdose are non-specific and are generally nausea, vomiting, diarrhoea and gastric upsets. Treatment is mainly supportive although gastric lavage will be necessary if a large amount has been ingested.
AbsorptionCefradine has a high degree of stability to many beta-lactamases. It has a low degree of protein binding and a large volume of distribution. Therefore, tissue levels are generally found to be high. Oral cefradine can be given twice or four times daily and is well absorbed. Cefradine is acid stable and is rapidly absorbed following oral administration in the fasting state.
DistributionFollowing doses of 250mg, 500mg and 1000mg average peak serum levels of approximately 9, 16.5, and 24.2 micrograms/ml, respectively, were obtained at one hour. The presence of food in the gastrointestinal tract delays the absorption but does not affect the total amount of cefradine absorbed. Measurable serum levels are present six hours after administration.
EliminationOver 90% of the drug is excreted unchanged in the urine within 6 hours. Peak urine concentrations are approximately 1600 micrograms/ml following a 250mg dose, 3200 micrograms/ml following a 500mg dose, and 4000 micrograms/ml following a 1000mg dose. After 48 hours administration of 100mg/kg/day of cefradine for the treatment of otitis media, cefradine has been measured in the middle ear exudate at an average level of 3.6 microgram/ml.
11th December 2018
Joshna House, Crowbridge Road, Orbital Park, Ashford, Kent, TN24 0GR
0845 437 5567
0845 437 5565
+44 (0)1233 506 574
0800 220 280